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Since January 2008, the Italian Regions, in accordance 
with their organizational programme, have launched the 
offer of free human anti-papillomavirus vaccine (HPV) 
to 12-year-olds, with the possibility to extend this offer 
to other age groups. With the beginning of this vaccina-
tion campaign, a widespread scientific debate developed 
concerning certain aspects which are still disputed. In our 
opinion, therefore, it was decided worthwhile making 
a review of articles appearing in the literature over the 
last year, in particular reports published after the onset 
of commercialisation, in the attempt to gather together 
useful elements that would contribute to improve the 
vaccination strategies.
Development, therefore, of a vaccine to reduce the impact 
of the infection, in terms of morbidity and mortality, has 
now become of prime importance as far as concerns pu-
blic health worldwide. 
The European Medicines Evaluation Agency (EMEA) 
has authorized the use of 2 anti-HPV vaccines: since Sep-
tember 2006, a quadrivalent vaccine (Gardasil®, Sanofi 
Pasteur MSD) containing Virus-like Particles (VLPs) of 
the HPV-16, HPV-18, HPV-6 and HPV-11 genotypes, 
produced in Saccharomyces cerevisiae and with an amor-
phous alluminium hydroxyphosphate sulphate (AAHS) 
adjuvant and, since September 2007, a bivalent vaccine 
(Cervarix®, GlaxoSmithKline) containing VLPs of the 
HPV-16 and HPV-18 genotypes, produced in insect 
cell lines and with the AS04 (aluminium and monopho-
sphoryl-lipid A hydroxy adjuvant). Since 2006, Garda-
sil®, has also been granted approval by the Food and Drug 
Administration (FDA) in the United States.
Treatment indications* for both these products are aimed 
at prevention of cervical precancerous lesions and cervical 
cancer caused by HPV 16 and 18, which are held respon-
sible for approximately 70% of all cases of cervical carci-
noma [1]; Gardasil® is used, furthermore, in the prevention 
of lesions correlated with HPV 6 and 11, responsible for 
70-90% of genital condylomas and 10-20% of low grade 
of Cervical Intraepithelial Neoplasia (CIN 1). Evidence that 
HPV 6 and 11 are associated with CIN 1 lesions confirms 
the significant frequency of these types in women with 
borderline cytological evidence, such as, abnormal Pap-
test, atypical squamous cells of undetermined significance 
(ASCUS) and atypical glandular cells of undetermined 
significance (AGUS) [2-5]. Gardasil® indications also in-
clude prevention of precancerous genital lesions at vulva 
(VIN 2/3) and vagina (VAIN 2/3) level. In this respect, one 
of the aims in the pharmaceutical development of vaccines 
was, indeed, that of extending the number of viral types of 
HPV in order to prevent the related pathological conditions, 
taking into consideration primarily cervical cancer, but not 
overlooking other tumours of the female genital tract and 
the early disorders, such as condylomas and low grade le-
sions correlated with the various viral types. The treatment 
used in the management of these lesions involves high costs 
which are not necessary and could, therefore, be limited 
with the use of a primary prevention programme [6, 7]. 
As far as concerns the host immune response, anti-HPV 
vaccines have been produced with an adjuvant in order 
to increase antibody response: it is well known, however, 
that the protection induced by these, even if mediated by 
the humoral response, cannot be correctly evaluated only 
by means of the immunological data, but need to be rela-
ted to prevention of clinical lesions. As mentioned in the 
technical notes of these two products, no minimal antibo-
dy level has been identified as associated with protection 
against CIN, grades 2 and 3, or against persistent infection 
associated with the types of virus contained in the vaccine. 
Also for this reason, World Health Organisation (WHO) 
recommended undertaking clinical developments with 
clinical-histological endpoints, aimed at the definition of 
“precursors” as the surrogate of carcinoma, based upon 
precise observations focused on the biological behaviour 
of the intra-epithelial lesions (CIN 1, 2 and 3) [8].
In clinical studies involving young women, both vaccines 
were found to be efficacious as far as concerns primary 
and secondary endpoints associated with the types of 
HPV contained [9]; moreover, Gardasil® was demonstra-
ted to be highly efficacious in the prevention of vaginal/
vulvar and genital condyloma lesions [10]. On the other 
hand, these two preparations do not appear to have any 
significant effect upon clearance levels and progression 
of the cervical infections caused by HPV [9], thus confir-
ming their preventive rather than their therapeutic role.
Furthermore, there is evidence of cross protection towar-
ds viral strains not directly contained in the quadrivalent 
preparation thus confirming the difficulty encountered in 
interpreting the mechanisms of the immune response and 
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the necessity in support of the assumption related to the 
need to refer to histological endpoints in order to evaluate 
efficacy. As reported in the technical note, the efficacy of 
Gardasil® against CIN and CIN 2/3 or adenocarcinoma in 
situ (AIS) caused by HPV not contained in the vaccine, 
but phylogenetically correlated to HPV 16 or HPV 18, 
has been evaluated in Phase III studies. After a mean 
follow-up period of 3.6 years, the results referring to the 
combined incidence of CIN 2/3 or AIS demonstrate a sta-
tistically significant efficacy (55.6% - 95% CI: 26.2-74.1) 
as far as concerns pathological conditions structurally cor-
related to HPV 16 (particularly HPV 31). Again, in the te-
chnical note, it is stated that the efficacy is not statistically 
significant for HPV types phylogenetically correlated to 
HPV 18 (including HPV 45). With regard to Cervarix®, 
it would appear from published data referring to the GSK 
001/007 trial, that the efficacy, calculated in the analysis 
(modified) intention-to-treat (MITT), was 94% (95% CI: 
63-100) for HPV 45 and 55% (95% CI: 12-78) for HPV 
31 [11], but only for the incident infection variable (only 
positivity to HPV). This study made no mention of effi-
cacy findings referring to the above-mentioned and more 
important histological endpoints. Again as far as concerns 
Cervarix®, in the MITT analysis performed in the PATRI-
CIA trial, the efficacy against persistent infection since 6 
months was found to be 60% (CI 97.9%: 3-85) for HPV 
45, 36% (CI 97.9%: 1-60) for HPV 31 and 32% (CI 
97.9%: 4-52) for HPV 52, while for persistent infections 
since 12 month 62% (CI 97.9%: -93; 95), 11% (CI 97.9: 
-115; 63), 47% (CI 97.9%:-12; 76), respectively [12]. 
Albeit, these results have not yet been included in the 
technical notes accompanying the product.
The fact that anti-HPV vaccination offers greater protec-
tion compared to specific types of the vaccines, represents, 
however, an incentive to further develop these preparations.
In studies on the immunogenicity, not only the bivalent 
vaccine but also the quadrivalent type, were found to 
be highly immunogenic with serum conversion rates of 
approximately 100% and, generally, after the third dose, 
peaks of geometric means of the circulating antibody 
titres (GMT) were observed from 10 to 100 times 
greater than those observed following a natural infec-
tion [11, 13]. Thereafter, a plateau has been shown, 
that remains stable throughout the period of follow-up 
(approximately 4 years) [11, 12, 14].
It is worthwhile pointing out that the immunogenicity 
tests, referring to the clinical trials, were performed by the 
manufacturers using two different systems to evaluate the 
post-vaccination antibody response, and, furthermore, it is 
important to note that the data related to long-term follow-
up would appear to be, partially, influenced, in the interpre-
tation, by the technique used to measure the antibodies.
In the clinical trials carried out with Gardasil®, antibodies 
were measured by means of type-specific immunological 
samples, in particular the competitive sample based upon 
Luminex (cLia) technology with type-specific standards, 
as shown in the technical notes. This sample measures the 
antibodies against a single neutralizing epitope for each 
VLP-HPV [15], therefore, this result causes a higher spe-
cificity regarding display of the humoral immune response 
produced following vaccination.. With regard to Cerva-
rix®, the IgGs were measured using a direct type-specific 
enzyme-linked immunosorbent assay (ELISA) [16], the 
intrinsic characteristic of which is the capacity to reveal 
total antibodies employing, during the solid phase, the anti 
VLPs L1; thus the ELISA test is able to evaluate the com-
plex of the humoral response following vaccination, albeit 
without discriminating between neutralizing and non-
neutralizing antibodies. Thus, considering the different 
methodological approach, direct comparisons between 
antibody titres with the cLia test and those obtained with 
ELISA are impossible and, consequently, also between 
the antibody “kinetics “of the curves. In addition, the va-
rious monoclonal antibodies, selected in the cLia method, 
display different affinities and perform in a different way 
according to the different HPV vaccine types, thus at the 
present state of our knowledge it is absolutely impossible, 
not only to compare the data concerning the quadrivalent 
vaccine with those of the bivalent vaccine, but there is not 
even a common reading of the antibody “kinetics” for the 
various types of VLP-HPV of the quadrivalent.
For example, the curves of the antibodies of the quadri-
valent vaccine reveal that during the long-term follow-up 
phase, in women vaccinated with Gardasil®, a reduction 
is observed in the percentage of serum conversion of 
almost one third for HPV 18 whilst this is not seen to 
occur for HPV 16, mentioning only the types at high risk. 
This finding, as previously pointed out, is technique-de-
pendent, therefore it is tempting to hypothesise that this 
is influenced by the characteristics of the response to the 
epitope selected for HPV 18. Albeit, this does not appear 
to be of clinical relevance inasmuch it was not found to be 
correlated, over time, with the loss of protection as far as 
concerns the clinical endpoint (CIN 3 or AIS) [13, 14].
Reports, so far concerning laboratory tests, clearly 
reveal the almost total lack of samples with which to 
evaluate antibody titres thus, from a practical viewpoint, 
no standard blood test exists with which these can be 
evaluated [8], despite the fact that the protection mecha-
nism of HPV vaccines is based upon the production of 
neutralizing antibodies, as stated in the technical notes. 
In conclusion, the above-mentioned data suggest that great 
caution should be taken when advancing hypotheses and 
expressing considerations concerning the antibody respon-
se, both from a qualitative and quantitative viewpoint. 
Again, as far as concerns the immunological response, 
further reflection, on this point, is triggered by the obser-
vation that the antibody response to the VLPs HPV 16 
is high following the administration of the quadrivalent 
vaccine as well as following vaccination with a similar 
preparation, namely, monovalent HPV 16 [17], thus 
demonstrating that there is no indication that the VLPs 
themselves exercise immunological disorders, when con-
tained in a multivalent preparation [9].
Another aspect to be taken into consideration concerns 
the immunological memory, a mandatory basis for long-
term protection.
Suggestions on how this immune memory for HPV 
vaccines should be investigated have been advanced by 
international organizations’ authorities [8]. For the qua-
drivalent vaccine, evidence of an anamnestic response has 
been observed in two different groups, the first one being 
HPV VACCINATION IN ITALY
127
vaccinated subjects serum positive to the relative types 
of HPV prior to vaccination, the second group refferd to 
vaccinated subjects who had received a challenge dose of 
Gardasil®, 5 years after the beginning of the vaccination 
cycle [14]. These results suggest a long-lasting type of 
vaccine efficacy and mathematical models estimated de-
tectable antibody levels ranging from at least 12 years to 
throughout lifetime [18]. As far as concerns the bivalent 
vaccine, no studies ad hoc have been reported in the litera-
ture evaluating the immune memory detected clinically.
VLPs comprise the capside protein which is highly im-
munogenic but is not infective since it has no DNA. Thus 
one would expect to find a safety profile similar to that in 
other structurally similar vaccines, such as, for example, 
that of tetanus and hepatitis B [9]. 
Safety data have been obtained in three clinical trials of 
phase III in which, in general, the vaccines were found 
to be well tolerated. Local reactions, such as pain and 
erythema at the site of administration [11-13, 17] were 
significantly more frequent than in the control group: 
local pain was reported in those subjects who received 
the vaccine and in the controls, 90.5% and 78.0%, respec-
tively, in the PATRICIA trial and 85.3% vs 75.4% in the 
FUTURE I trial [12, 17]. 
Systemic adverse events, potentially correlated with the 
vaccine, such as fever, for 7 days following vaccination 
in 12.4% of those vaccinated and in 10.9% of controls in 
the PATRICIA trial, or fever for the first 5 days reported 
by 14.8% of those vaccinated and by 11.5% of controls, 
in the FUTURE I trial. Neither local nor systemic symp-
toms were more severe in the successive administrations 
or in women with previous exposure to one of the types 
contained in the vaccine [17].
Data regarding current post-marketing monitoring concern 
primarily Gardasil®: the largest amount of surveillance data 
have been produced by the USA drug vigilance system 
where, following FDA authorization, more than 20 million 
doses have been used. Records were collected in the Vac-
cine Adverse Event Reporting System (VAERS), in the 
Vaccine Safety Datalink Project and in the Clinical Immu-
nization Safety Assessment Network. Based upon reports 
recorded from 2006 to 31/8/2008, 94% of the cases were 
not severe adverse events, such as weakness, pain in the 
administration site, headache, nausea and fever. All severe 
adverse events reported (neuropathy, peripheral paralysis, 
Guillain-Barré Syndrome, thrombo-embolic events etc), 
were scrupulously analysed and were not correlated with 
the vaccine administration [19]. On the basis of this infor-
mation, Centers for Disease Control and Prevention (CDC) 
and FDA defined Gardasil® safe and efficacious in the pre-
vention of infections of the 4 types present in HPV. 
As far as concerns Italy, the Agenzia Italiana del Farmaco 
(AIFA) (Italian drug agency) authorized the commercia-
lisation of the two HPV vaccines in 2007 (Determination 
of 28 February for Gardasil® and 21 November for Cerva-
rix®) and defined that the preparations, in the H-RR group, 
should be made available not only free-of-charge to all 
12-year-old females, but also be made available, on sale, 
at the Chemists. Choice of this strategy is in keeping with 
the recommendations of the World Health Organization 
(WHO) [20] and with the scientific evidence currently 
available, according to which the efficacy of the prepara-
tion is based upon immune protection before an eventual 
HPV infection. The most rational and efficient way of 
using this new vaccine is, therefore, to actively offer it im-
mediately prior to the beginning of sexual activity and age 
12 years was found to be best indicated, because, in this 
age period, the immune response is higher than that in the 
years immediately following [21]. Furthermore, coinciding 
with the compulsory school period, there would be a grea-
ter opportunity for families to communicate with health 
and social workers, thus the offer of vaccination, in this 
age group, would imply that it be performed through the 
same services as those already actively involved in infant 
vaccination, thus maintaining this service in the environ-
ment of the professional patrimony and of the programme 
of the National Health Service, also bearing in mind other 
important professional figures (specialists in Gynaecology 
& Obstetrics, Paediatricians in Private Practice, General 
Medicine Doctors Practitioners, Health Assistants…).
The strategy used in the active offer of the HPV vaccine 
in Italy was defined in Conferenza Stato-Regioni (Con-
ference of State-Regions) (20/12/2007) therefore, from 
January 2008, each Region, according to its organizatio-
nal procedure, was able to proceed with the vaccination 
campaign, with the possibility to extend it to other age 
groups [22]. In order, not only to guarantee fairness ac-
cess and parity of offer, but also to monitor coverage of 
vaccination, at Regional level, the ministerial regulations 
invites the health services to record, the vaccinations 
performed in the respective database. This system would 
also make communication easier as far as concerns the 
organization of screening programmes: there is, in fact, 
the not negligible risk that the increase in vaccination 
coverage would be accompanied by a decrease in com-
pliance by the women who had received the vaccine. 
Above all, considering the fact that approximately 30% 
of cervical lesions are not caused by types 16 and 18, it is 
possible that a considerable increase might occur in inci-
dence and mortality rates in those women not taking part 
in the screening programme, with consequent reduction 
of vaccine effectiveness [23]. This is why it is mandatory 
for the offer of vaccination to be strategically integrated 
in the programmes, already under way, of secondary 
prevention, which, moreover, represent an instrument re-
vealing the trend of pre-cancerous lesions and of cervical 
carcinoma and, thus, the evaluation of the efficacy of the 
extended immunisation programme. 
With regard to coverage, the aims are to reach at least 95% 
of the target population, with three doses of vaccine, within 
the five years since the beginning of the vaccination pro-
gramme, that is, for girls born in 2001, who will be actively 
invited for vaccination in 2012 and whose coverage for the 
third dose will be evaluated on 31st December 2013. 
Also the possibility to have two products available, which 
have been demonstrated to be efficacious and well tolera-
ted, have led to good results being obtained, as far as con-
cerns vaccination coverage at territorial level: for example, 
based upon preliminary data recorded in the Basilicata Re-
gion, referring only to the 12-year-olds, coverage reached 
77%, for the 15-18-year-olds, 67% and 64%, respectively, 
whilst for 25-year-olds only 37% was reached.
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Nevertheless, according to those responsible for decision-
making at Public Health level, a better understanding 
of some important aspects is necessary, since they still 
remain to be fully elucidated: the efficacy, immunoge-
nicity and the long-term safety profile, the possibility to 
simultaneously administer other vaccinations, the even-
tual need to proceed with booster doses. Likewise, further 
information on the performance of vaccination in mature 
women, in immunodeficient subjects, in young women 
with previous exposure and in men, could become availa-
ble in the near future, when the results of the clinical trials 
performed in these groups of subjects are published.
In the light of these considerations, it would be inte-
resting to take a closer look at those aspects, which 
still remain to be fully elucidated, possibly, in a forum 
focusing on contributions not only from experts in the 
field but also on queries submitted by readers to the 
Editorial Board of the Journal of Preventive Medicine 
and Hygiene.
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